December 17, 2009 (FinancialWire) (Investrend Information Syndicate) — Pharmacyclics, Inc.’s (NASDAQ: PCYC) first quarter 10-Q and recent 10-K filings are available for shareholders and potentially interested investors.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. The company’s products in clinical development includes HDAC Inhibitor for advanced solid tumors, recurrent lymphomas, and sarcoma; Factor VIIa Inhibitor for cancer therapy; B Cell Tyrosine Kinase Inhibitor for the treatment of B-Cell lymphomas, and autoimmune diseases and mast cell diseases; and MGd for primary brain tumor and childhood brain tumors. Its pre-clinical development products comprise B Cell Tyrosine Kinase Inhibitors for autoimmune disease and mast cell disease; and HDAC8 Inhibitors for the treatment of autoimmune and cancer. The company was founded in 1991 and is headquartered in Sunnyvale, California.

The company’s current market capitalization is approximately US$ 146.7 million. PCYC’’s stock last closed at US$ 2.92 per share.

The company’s free reports are available via the Free Annual Reports Service (at http://investrend.ar.wilink.com/?level=279) by entering “Pharmacyclics” into the search field.

The Annual Reports Service is a free service sponsored by the service’s hundreds of participating companies. Companies participate in order to serve the investing public through greater transparency. Other recent company filings and reports available via the Annual Reports Service include F & C Capital & Income Investment Trust PLC (LSE: FCI), Sarantel Group PLC (LSE: SLG), Niusule Biotech Corp. (OTCBB: NIUS), JPMorgan European Investment Trust PLC (LSE: JFF), Ecofin Water & Power Opportunities PLC (LSE: ECWO), Invesco Property Income Trust Ltd. (LSE: IPI), Hansa Trust PLC (LSE: HAN) (OTC: FSBTF), Perpetual Income & Growth Investment Trust PLC (LSE: PLI), New India Investment Trust PLC (LSE: NII), JPMorgan Fleming Smaller Japanese Companies Investment Trust PLC (LSE: JPS), Edinburgh Investment Trust PLC (LSE: EDIN) (OTC: EHITF), Armour Group PLC (LSE: AMR), Bravo Venture Group Inc. (TSX Venture: BVG), Bellway PLC (London Stock Exchange: BWY) (OTC: BLWYF), Chase Corporation (AMEX: CCF), Continental Materials Corp. (AMEX: CUO), Amcon Distributing Company (AMEX: DIT), Eaton Vance Enhanced Equity Income Fund (NYSE: EOI), Majedie Investments PLC (London Stock Exchange: MAJE) (OTC: MJENF), Morgan Stanley Income Securities, Inc. (NYSE: ICB), Grainger PLC (London Stock Exchange: GRI) (OTC: GRTGF), Eaton Vance Insured Municipal Bond Fund (AMEX: EIM), PIMCO High Income Fund (NYSE: PHK) and Shaw Communications, Inc. (NYSE: SJR).

FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate also provides complete, daily conference call schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “Daily FirstAlert(tm)” (http://www.financialwire.net/news-alerts/). Recently webcast company presentations, financial results & earnings calls now available through VCall/WILink include InSite Vision, Inc. (OTCBB: INSV), LocatePLUS Holdings, Inc. (OTC: LPHC), Rentech, Inc. (AMEX: RTK), CytRx Corp. (NASDAQ: CYTR), Santarus, Inc. (NASDAQ: SNTS) ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Methode Electronics, Inc. (NYSE: MEI), White Electronic Designs Corporation (NASDAQ: WEDC), Cantel Medical Corp. (EXCH: CMN), Frequency Electronics Inc. (EXCH: FEIM), Pep Boys-Manny, Moe & Jack (NYSE: PBY) and Xeta Technologies, Inc. (NASDAQ: XETA). Recordings are accessible via the search function at http://infoescrow.net/f/?u=http://www.investorcalendar.com by entering any company’s ticker symbol into the search field.

(Source for company description: Pharmacyclics, Inc.)

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[corprtflng] [frannlrprts]